Elabscience

Recombinant Mouse Kallikrein 7/KLK7 Protein (His Tag)(Active)

Product Code:
 
PKSM040437
Product Group:
 
Recombinant Proteins
Supplier:
 
Elabscience
Host Type:
 
Mouse
Regulatory Status:
 
RUO
Shipping:
 
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
 
Generally lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
PKSM040437-20ug20ug£664.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: China.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Abbreviation:
Kallikrein 7;KLK7
Accession:
Q91VE3
Activity:
Measured by its ability to cleave the fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2 (AnaSpec, Cat#27114). The specific activity is > 70 pmoles/min/ug. (Activation description: The proenzyme needs to be activated by Thermolysin for an activated form)
Background:
Kallikrein-7, also known as kallikrein-related peptidase 7, Stratum corneum chymotryptic enzyme, Serine protease 6, KLK7, and PRSS6, is a secreted protein which belongs to thepeptidase S1 family and Kallikrein subfamily. Members of the Kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14). Kallikrein-7 / KLK7 appears to be increased in ovarian cancer and higher KLK7 expression in ovarian cancer tissue is associated with poorer prognosis of ovarian cancer patients. Kallikrein-7 / KLK7 is abundantly expressed in the skin and is expressed by keratinocytes in the epidermis. Kallikrein-7 / KLK7 is up-regulated in ovarian carcinoma, especially late-stage serous carcinoma, compared with normal ovaries and benign adenomas (at the protein level). It was significantly associated with shorter overall survival (OS) and disease-free survival (DFS). Kallikrein-7 / KLK7 may catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. KLK7 also plays a role in the activation of precursors to inflammatory cytokines.
Calculated MW:
26.5 kDa
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
HEK293 Cells
Formulation:
Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
C-His
Purity:
> 95 % as determined by reducing SDS-PAGE.
Sequence:
Met1-Arg249
Target Synonym:
Kallikrein-7;Klk7;Serine protease 6;Stratum corneum chymotryptic enzyme;Thymopsin;kallikrein-related peptidase 7;PRSS6;SCCEkallikrein-7;SCCE
UNIProt ID:
Q91VE3

Documents